In February of this year, Dr. Solomon Kamson published a paper in the Journal of Clinical Medicine Research regarding a study he participated in that showed patients can experience less pain following lumbar decompression surgery. Using a supplemental orthobiologic during surgery led to patients feeling less pain and experiencing better improvement compared to patients who did not receive a supplementary orthobiologic.
About this Study
Endoscopic-assisted lumbar decompression surgery is a minimally invasive surgery known to reduce collateral tissue damage, incisional pain, recovery time and complications. While most patients feel relief after this surgery, some continue to have persisting pain. It is believed that this pain is related to the neuroinflammatory pathways.
Fortunately, it is possible to control this inflammation by inhibiting certain cell-to-cell communication through the use of the biological intervention. Two common biologics used for this intervention are an amniotic-derived product (ADP) and bone marrow aspiration (BMA). ADP reduces inflammation by reducing pro-inflammatory cytokines, increasing anti-inflammatory cytokines, and inducing pro-inflammatory cell death. BMA stem cells have an ability to control neuro-inflammation as well, and there is evidence to suggest that it does so by inhibiting monocyte infiltration, activation of the glia, and cytokine production in the spinal cord.
This study found that orthobiologic supplementation of BMA and ADP improved pain control in early post-operative periods for patients. Results showed significant improvement, especially when compared to standard micro-discectomy post-surgery results.
The results of this study show that there is a strong potential for the application of ADP and BMA in the recovery process of patients who have undergone lumbar micro-discectomy.
You can learn more and read the details of this study in the Journal of Clinical Medicine Research here.